

Betsi Cadwaladr University Health Board

Minutes of the Quality, Safety & Experience Committee meeting held on 20 January 2023 Via Teams

Present:

Lucy Reid Independent Member (Chair)
Cheryl Carlisle Independent Member – from 10:00

Jacqueline Hughes Independent Member John Gallanders Independent Member Hugh Evans Independent Member

In Attendance:

Peter Bohan Associate Director of Occupational Health Safety and Security
Gareth Evans Acting Executive Director of Therapies & Health Science

Matthew Joyes Associate Director of Quality
Phil Meakin Associate Director of Governance
Teresa Owen Executive Director of Public Health
Philippa Peake-Jones Head of Corporate Affairs (minutes)

Angela Wood Executive Director of Nursing and Midwifery

Nick Lyons Executive Medical Director
Molly Marcu Interim Board Secretary
Mike Smith Project Lead Mental Health

Gaynor Thomason Programme Director for Clinical Safety Improvement (for part)

Paul Lumsdon Interim Director of Nursing Mental Health

Rod Taylor Director of Estates (for part)
Ben Thomas Consultant Nephrologist
Karren Mottart IHC Medical Director (for Part)
Barbara Cummings Interim Director of Performance

Fflur Jones Audit Wales

Jackie Allen CHC

Agenda Item Actio	n
OPENING ADMINISTRATION	
QS23.01 - Welcome, Introductions and Apologies for Absence	
QS23.01.1 Apologies were received from Chris Stockport, Executive Director of Transformation and Planning, Sue Green, Executive Director of Workforce and Organisational Development, Dave Harries, Internal Audit and Iain Wilkie, Interim Director of Mental Health.	
QS23.02 - Declarations of Interest on current agenda	
QS23.02 There were no declarations of interest noted.	
QS23.03 - Minutes of Previous Meeting Held in Public for Accuracy	

QS23.03.1 It was resolved that the minutes were approved as an accurate record of the meeting held on 1 November 2022 **QS23.04 - Matters Arising and Table of Actions** QS23.04.1 The Action log was reviewed in detail and where appropriate actions were removed. It was noted that actions should be completed before the next meeting and if this were not possible an update in the action log noted as to why. QS23.04.2 The Committee reviewed the action log and closed actions where appropriate. QS23.05 - Patient Story QS23.05.1 The Committee viewed a video on a patent who shared her experience through diagnosis and treatment of Pulmonary Embolisms (PE) in Ysbyty Glan Clwyd. The Associate Director of Quality thanked Catrin for sharing her story and highlighted the leaning identified in the paper. QS23.05.2 The Executive Medical Director advised that improvement work needs to be NL undertaken in this area and advised that he would work outside the meeting to confirm that the patient was receiving the correct medication and support psychologically. QS23.05.3 A discussion took place around different experiences of care with regards to PE experienced across the Health Board and the Executive Director of Nursing and Midwifery advised that training, information and communication would be replicated across the Health Board to ensure consistency but that the management of PE varies across the UK. ΑW QS23.05.4 It was agreed that actions from the patient stories would be reviewed at the new Oversight and Assurance Group and report back into QSE through the Executive Director of Nursing and Midwifery's Chair's Assurance Report. QS23.05.5 It was agreed that there would be a year-end report received at QSE on AW Patient Stories. QS23.05.6 It was resolved that the Committee receive and reflect upon the story QS23.06 - Corporate Risk Register [Director of Estates joined the meeting] QS23.06.1 Attendees discussed the Health and Safety risks in depth around Estates discussing in detail the risk around the likelihood of a legionella outbreak. It was noted that there are controls and mechanisms in place to reduce the exposure but that there was an inherent challenge with water quality, management and usage but that the likelihood was low but the impact would be great. Questions were raised in relation to the score of the risk and it was noted that this risk rating had been identified by Corporate Health and Safety but that it would be reviewed to see if the scoring could be reduced through evidence. The Board Secretary queried the methodology applied, that there was a lack of tangible justification for the risk rating. The Director of Estates agreed to review RT the risk rating.

QS23.06.2 Attendees discussed the fire safety risk noting that the issue with this risk was the level of consistency across all sites and ownership on each site. The Board

Secretary clarified the identification of a risk exposure due to certain things not taking place, noting that there had not been any reportable incidents, she queried what was within the gift to implement and that there was a need to do something differently. It was acknowledged that a lot of the issues were in relation to capital funding. It was agreed that the Board Secretary and the Director of Estates would meet to identify what risks were in relation to capital funding and report back to the committee. An Independent Member declared an interest as a Health and Safety Representative.

MM/RT

QS23.06.3 Attendees noted that the Risk Management Group was stood down in December due to Industrial Action and that papers had been circulated by email but that they had not been scrutinised in a meeting. It was agreed that the role of the Risk Management Group was to challenge the score and that what was not being identified was site ownership of risk management.

QS23.06.4 Attendees discussed the de-escalation of two vascular risks and that due to the Risk Management Group being stood down these had not been considered in detail despite recommendations being received by members of the Risk Management Group and then the HBLT. The Associate Director of Governance advised that it was his proposal to look at the risks in detail at these groups.

QS23.06.5 The Executive Medical Director clarified the reasoning behind the deescalation of the Vascular Risks advising that following consultation with colleagues, in his opinion it was correct that they be reduced. It was noted that there should however be a new risk that the Vascular Steering Group have raised which relates to the wider sustainability of the Vascular Service.

QS23.06.5 Attendees discussed due process and that evidence was required and submitted to the QSE Committee should any risk being proposed for downgraded. The Board Secretary endorsed the process, that it was the Committees responsibility to challenge and hold the ring on de-escalation and that when this was being considered timing is identified. It was agreed that there was a need to ensure that there was a consistent approach. The Board Secretary suggested that a template was produced to alleviate the requirement of going toing and froing between meetings and that the challenge was with the Risk Management Group to ensure evidence was clear when risks are changing status.

PΜ

QS23.06.5 It was agreed that at the next QSE Committee there would be a deep dive on the Vascular Risks.

PM

QS23.06.X It was resolved that the Committee reviewed and discussed the report and agreed that Vascular risks should not be downgraded and reinstated at its previous level until it had been through due process.

QS23.07 Polices for Approval

[Consultant Nephrologist joined the meeting]

QS23.07.1 The Consultant Nephrologist presented the policy advising that he had been the National Lead for Consent. It was noted that the narrative on the coversheet supported how the policy would be implemented. Clarification around the data was shared with regarding compliance around peer auditing. The Consultant Nephrologist advised attendees that the concerning statistic was the 75% of the time that the patient leaflets had not been provided. The Executive Medical Director thanked those who had been involved in producing the policy noting that due to the national leadership role the Health Board was ahead of the curve.

QS23.07.2 Attendees noted that the track changes were showing in the document to show that comments had been included in the most up to date version. It was discussed that a policy is only as good as it's usage and that it was a very long policy but clear that was the reason an executive summary had been produced. QS23. 07.3 It was resolved that the Committee approved the Consent to examine or treatment Policy QUALITY SAFETY AND IMPROVEMENT **QS23.08 - Mental Health Outcomes and Improvement** QS23.08.1 The Executive Nurse Director shared that she thought the paper was very informative but questioned the data source on page four and the length of time that the work identified on page six was going to take. The Interim Nurse Director agreed to review page 4 of the report where it said "data source" rather than the dates and review the HCA numbers and amend the report for the next Committee. It was noted PLthat with reference to the work being undertaken on page 6, that the timing of 10 months to triangulate was too long. QS23.08.2 It was noted that the outstanding actions are the focus and that a risk ы assessment would be completed on the actions and notify the Committee if there are any concerns that deadlines would not be met. QS23.08.3 The Committee were informed that by the end of February all band 5 staff will be given training on risk assessment and suicide training and that this would be documented. QS23.08.4 The work on auditing risk assessments is ongoing and a weekly meeting takes place to understand how improvements can be made. It was noted that some beds which were identified as anti-ligature are now not and that to mitigate the capacity around health and safety this is now being bought in. QS23.08.5 A discussion took place around staffing and training, noting that the 100% figure for staff being trained in risk assessment and suicide was for those in post. The Executive Director of Nursing advised that clinical ownership was essential and the Project Lead Mental Health confirmed that the Ward Managers, Matrons and Heads of Nursing were doing the spot checks. It was noted that a lot of hooks had been put on walls given the increase in corridor nursing and that these should be included in risk assessments. QS23.08.6 It was requested that with regards to the outstanding actions for the Notice of Contravention outcomes were required and the Project Lead for Mental Health agreed to MS review the digital patient record system to ensure that all those who needed access to the system would be able to access it. QS23.08.7 It was resolved that Committee reviewed the proposed update on the development of the MH&LD Divisional Improvement Plan. QS23.09 - YGC Improvement Plan

QS23.09.1 Attendees received the YGC Improvement plan noting that it had been scrutinised in a lot of detail at Cabinet. Patient bounce back is a measure that is being

recorded and this was being done over a 72-hour period without concerns currently being raised. What was being identified as the main concern was the closure of nursing homes and staffing. It was noted that what was once best practice is now no longer supported but the Health Board is looking at home support and maximising Community Hospitals. Clarity was given in relation to rehabilitation, care homes and hone setting discharge. Concern was raised in relation to Local Authority budgets

QS23.09.2 An Independent Member queried whether there was an improvement in documentation being seen, and if cancer patients in crisis were being able to be seen at the cancer centre. The Programme Director for Clinical Safety Improvement advised that the IHC's were doing documentation audits and improvement has been seen but there is further work to be done.

QS23.09.3 The Executive Medical Director advised that there was a requirement to look at multidisciplinary team notes on cancer and though improvements were being seen further work was being done, specifically around weekend and bank holidays and that the information was being reviewed at the forthcoming Cancer Partnership Board.

QS23.09.4 An Independent Member queried consultants and recruitment in terms of overall safety and assurance and how often the Health Board was running below capacity and what impact that was having on patients. The Executive Medical Director advised that there was some ongoing debate as to whether the traditional staffing model is effective, however, it was noted that the Health Board is below RCEM Standards and that it was mitigate through a high volume of agency staff, which introduced its own risk and problems, however, if the Health Board were to benchmark it was in a better place than others.

QS23.09.5 The Programme Director for Clinical Safety Improvement advised that there is work ongoing to look to appoint consultant nurses and are consultant physiotherapists.

QS23.09.6 An Independent member questioned medical oversite on the Emergency Department at YGC and Paediatrics, given that it was now common practice to see patients waiting outside of the waiting room. The Executive Director of Nursing and Midwifery advised that from a nursing perspective, there is a Nurse in place and Health Care Support Workers are there providing refreshments. Audits are taking place to ensure that this is taking place and nurses are speaking to patients outside. It was acknowledged that the workforce is under extreme pressure.

QS23.09.7 It was resolved that the Committee noted the progress made to date on the YGC Improvement Plan.

QS23.10 - Vascular Improvement Plan

QS23.10.1 The Committee received the Vascular Improvement Plan an Independent Member highlighted that it was documented that there were still some issues with regards to record keeping and that he had heard that some patients were moving from a vascular route to an orthopaedic route. Clarification was sought on the proposed reduction of the staffing risk down to a tier 2 and if this identified that there were now enough consultants recruited. Finally, clarification was sought on the timing of the HIW report.

QS23.10.2 The Executive Medical Director advised that there had not been a change in policy with regards to the treatment of patients. With regards to the workforce, the consultant workforce is at establishment but with locum reliance. Attendees noted that a middle grade rota was now in place. Further recruitment around nursing, phycology etc

has been paused at the current time due to funding. Finally, the Executive Medical Director advised that it was anticipated that the HIW report would be received in March.

- **QS23.10.3** The Executive Medical Director advised that the report received was a little sparse due to a number of meetings being stepped down due to industrial action and that a fuller report would be received at the Vascular Steering Group and then onto the March QSE meeting.
- **QS23.10.4** An Independent Member advised that he would email the Executive Medical Director his operational queries outside of the meeting.

QS23.10.5 The Executive Director of Nursing and Midwifery updated on the conversations taking place with Welsh Government noting that what the Health Board is experiencing with regards to vascular is the same as other Health Boards.

QS23.10.6 A discussion took place with regards to the pathways matching the improvement plan, it was noted that a meeting had been scheduled to review what has been achieved with regards to the pathways and what is still yet to do

[The Programme Director for Clinical Safety Improvement left the meeting]

QS23.10.7 It was resolved that the Committee noted the summary of actions taken since the last update.

QS23.11 - Urology Improvement Plan

[The IHC Medical Director joined the meeting]

- **QS23.11.1** The IHC Medical Director presented the report. An Independent Member raised concerns around harm and waiting lists. It was noted that optimising pathways and centres of excellence would be utilised to reduce patient harm, an example of how this is being undertaken with the prostrate cancer pathway was shared.
- **QS23.11.2** The IHC Medical Director advised that with regards to streamlining waiting lists this was in relation to reducing steps that do not add value, for example following GP referral a patient should be able to go straight to diagnostics rather than via a consultant.
- **QS23.11.3** The Executive Medical Director advised that since the production of the paper two issues have been identified and that a response was being drafted to HIW around urology cancer wait lists.

QS23.11.4 Attendees discussed the robotic surgery, consultant training and the choice of robot purchased. It was noted that further conversations around procurement and the Urology HIW response would be taken outside of the meeting.

NL

JG

QS23.12 Patient Safety Report

This item was taken as a consent item due to timing, any questions should be forwarded and appended to the minutes with responses.

QS23.13 - Patient and Carer Experience Report

This item was taken as a consent item due to timing, any questions should be forwarded and appended to the minutes with responses. QS23.14 - HIW Update This item was taken as a consent item due to timing, any questions should be forwarded and appended to the minutes with responses. QS23.15 - Quality/Safety Awards and Achievements This item was taken as a consent item due to timing, any questions should be forwarded and appended to the minutes with responses. QS23.16 - Health and Safety Report including HSE Update QS23.16.1 The Committee received the Health and Safety Report an Independent Member queried if there was any way to highlight racially motivated incidents, it was noted that this was done and submitted to the equities group. QS23.16.2 Attendees discussed walk abouts and inspections, it was noted that a range of areas ae reviewed and that a detailed plan could be brought back to QSE Committee with clarity around Primary Care. QS23.16.3 The Board Secretary highlighted the Health and Safety gap analysis plan and noted that given this was the basis on which work was prioritised it needed to be seen. The Associate Director of Occupational Health Safety and Security advised that the gap analysis was used to develop the three year strategy which had been shared at QSE in the past. QS23.16.4 The Committee noted that further work was ongoing around falls given the data was not showing sufficient improvement. The Executive Director of Nursing and Midwifery advised that her senior team were looking at how to take this forward. QS23.17 - Nurse Staffing Act This item was taken as a consent item due to timing, any questions should be forwarded and appended to the minutes with responses. **REPORTS** QS23.18 - Chair's Assurance Reports This item was taken as a consent item due to timing, any questions should be forwarded and appended to the minutes with responses. **QS23.19 - Infection Prevention Report** This item was taken as a consent item due to timing, any questions should be forwarded and appended to the minutes with responses. QS23.20 - Quality & Performance Report

This item was taken as a consent item due to timing, any questions should be forwarded

and appended to the minutes with responses.

CLOSING BUSINESS

QS23.23 - Issues Discussed in Previous Private Session

QS23.21 The Committee noted that the items that were discussed in the private session on 1 November 2022 were:

- Update on Mental Health Investigations presented by the Executive Director of Public Health
- Incident Report presented by the Executive Director of Nursing and Midwifery
- Health & Safety Executive Compliance Update presented by the Executive Director of Workforce and Organisational Development

QS23.22 - Date of next meeting

QS22.255.1 It was noted that the next QSE Meeting would be held on 7 March 2023.

QS23.23 Exclusion of Press and Public

QS23.23.1 It was resolved that representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest in accordance with Section 1(2) Public Bodies (Admission to Meetings) Act 1960.